Confirmation of the regulation 251 of the Human Medicines Regulation following the Brexit transition. The MHRA announces that the UK remains a member of Council of Europe and the European Pharmacopoeia following the Brexit transition. So, products in the UK are expected to meet the standards published by the Brexit Pharmacopoeia (which are reproduced from the European Pharmacopoeia) after the transition period.
March 31, 2021